Skip to content
value.today

Romark Global Pharma, LLC

🇺🇸 Guaynabo, Puerto Rico, USAPharmaceuticalsFounded 2014
Total raised
$11 M
1 round on record
Latest round
$11 M
Oct 2015
First round on record
Oct 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Romark Global Pharma, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2015$11 MNo. 1$10 to $50 million

Romark Global Pharma, LLC: Raise no. 1, Oct 2015

Investors in this round

26 investors had bought by the notice of Feb 24, 2016: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $50 M offered; $39 M still to sell
Smallest investment taken
$100,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in Puerto Rico

People named in the notice

  • Brian S. Schnieders · Executive Officer
  • Celine S. Rossignol · Executive Officer
  • Jean-Francois Rossignol, M.D., Ph.D. · Executive Officer, Director, Promoter
  • Marc S. Ayers · Executive Officer, Director, Promoter
  • W. Andrew Krusen Jr. · Director
  • W. Seymour Holt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Francisco Jose Rivera (CRD 2303039) · broker-dealer Pariter Securities, LLC (CRD 127836) · Guaynabo, Puerto RicoSold in PR

Remarks in the notice

  • On fees: “Commissions paid will be based on 3% of the gross proceeds raised in the offering through the services of the placement agent.”

Signed by Marc S. Ayers, Manager of Romark UP, LLC, an Unlimted Partner. Source: SEC Form D, newest notice filed Feb 24, 2016. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Romark Global Pharma, LLC chose not to state its revenue in its newest notice of a funding round (Feb 2016).

    SEC Form D · Feb 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2016

That is all the official record says: Romark Global Pharma, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Romark Global Pharma, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Romark Global Pharma, LLC
NameRoleNamed in
Brian S. SchniedersExecutive officerFeb 2016
Celine S. RossignolExecutive officerFeb 2016
Jean-Francois Rossignol, M.D., Ph.D.Executive officerFeb 2016
Marc S. AyersExecutive officerFeb 2016
Jean-Francois Rossignol, M.D., Ph.D.DirectorFeb 2016
Marc S. AyersDirectorFeb 2016
W. Andrew Krusen Jr.DirectorFeb 2016
W. Seymour HoltDirectorFeb 2016
Jean-Francois Rossignol, M.D., Ph.D.PromoterFeb 2016
Marc S. AyersPromoterFeb 2016